

REMARKS

The new claims are drawn to methods for preparations of vaccines and vaccine compositions for use in treating allergies, cancer, or a biologic threat agent with a proteosome-protein antigen mixture. Support for the new claims is found throughout the specification. More particularly, support for claims 35-57 can be found on page 1, line 5-7; page 8, lines 25-28; and page 13, lines 8-14. Additional support for claims 52-55 can be found on page 10, lines 3-8. Additional support for claims 47-49 can be found on page 10, lines 12-21. Support for claims 39 and 44 can be found on page 9, line 23 to page 10, line 2.

Please also consider under the duty of disclosure, US Application 09/043,529, which as been allowed.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "Version with markings to show changes made". Applicants believe the claims presented herein are in condition for examination. The Examiner can contact the undersigned at 858-720-7960 with any questions regarding the instant application. In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing docket no. 405352000600.

Respectfully submitted,

Dated: June 7, 2002

By:

Karen B. Dow  
Karen B. Dow  
Registration No. (29,684)

Morrison & Foerster LLP  
3811 Valley Centre Drive  
Suite 500  
San Diego, California 92130-2332  
Telephone: (858) 720-7960  
Facsimile: (858) 720-5125

7

Serial No. 09/788,280  
Docket No. 405352000600

sd-89730

**VERSION WITH MARKINGS TO SHOW CHANGES MADE****In the Claims:**

Please amend the following claims:

7. A method to prepare a vaccine effective against infection which method comprises:
- providing a mixture of at least one protein antigen with a proteosome preparation in the presence of a detergent;
  - removing detergent from said mixture by diafiltration or ultrafiltration to obtain a proteosome-antigen composition; and
  - formulating said composition into a vaccine
- wherein the ratio of proteosomes to [viral] antigen in said mixture is greater than 1:1.

31. A composition prepared as described in claim 1 which is[can be] filtered with a 0.2 or 0.8  $\mu$ m filter [prior to formulation or filling].

32. A composition prepared as described in claim 7 which is[can be] filtered with a 0.2 or 0.8  $\mu$ m filter [prior to formulation or filling].

33. A composition prepared as described in claim 14 which is[can be] filtered with a 0.2 or 0.8  $\mu$ m [filter prior to formulation or filling].

34. A composition prepared as described in claim 19 which is[can be] filtered with a 0.2 or 0.8  $\mu$ m filter [prior to formulation or filling].